CSL Behring and Bayer Extend Agreement for Supply of Helixate Recombinant Coagulation Factor

Global distribution deal extended through 2017

KING OF PRUSSIA, Pa., February 01, 2007 /PRNewswire/ -- CSL Behring announced today that it has reached an agreement with Bayer HealthCare LLC to continue the supply and distribution of an important therapy for the treatment of hemophilia A.

Under the contract extension, Bayer will continue to supply Helixate (R) recombinant coagulation Factor VIII to CSL Behring through 2017. Additionally, Bayer was granted a license to intellectual property related to recombinant FVIII. At the same time, the companies settled outstanding litigation relating to the supply of recombinant Factor VIII. Terms of the settlement were not disclosed.

"Securing the long-term supply of this life-saving therapy is significant for the patient communities we serve," said Peter Turner, President of CSL Behring. "Under this agreement we will have the ability to increase the supply of Helixate available for our customers. We highly value our long-term relationship with Bayer and look forward to continuing it through the next decade."

"We strongly believe that this agreement can further develop our factor VIII franchise and that the new deal terms are attractive for both companies. It also solves all outstanding litigations," said Dr. Gunnar Riemann, Board Member Bayer HealthCare AG. "This is also a collaboration that has served the global hemophilia community through expanded distribution of our reliable Kogenate(R) and Helixate(R) line of products; reliability demonstrated by nearly two decades of clinical experience and more than 6 billion units infused," added Riemann.

About Helixate FS

Helixate FS is a recombinant factor VIII (FVIII) product used to treat hemophilia A when there is a demonstrated deficiency of FVIII, a plasma clotting factor. Helixate FS should be administered cautiously in patients with previous hypersensitivity to constituents of FVIII or known sensitivity to mouse or hamster protein.

Helixate FS should not be used by people with von Willebrand disease because it does not contain von Willebrand factor -- a different protein associated with a different bleeding disorder. For more information about von Willebrand disease, please visit allaboutbleeding.com. Adverse events are generally minor. The most common events include injection-site reactions, dizziness and rash.

For more information about Helixate FS, please see the full prescribing information at www.hemophiliamoms.com.

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of immune deficiency disorders, hemophilia, von Willebrand disease and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of shock and burns. The company also operates one of the world's largest fully-owned plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.

CONTACT: Sheila A. Burke, Director, Public Relations& Communications,Worldwide Commercial Operations, +1-610-878-4209, sheila.burke@CSLbehring

Web site: http://www.cslbehring.com/http://www.hemophiliamoms.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: February 2007


View comments

Hide
(web2)